OTCPK:MEDVF - Post by User
Post by
Hiddensecretson Mar 17, 2021 6:31pm
129 Views
Post# 32822414
Telehealth - Such a big DISAPPOINTMENT per analysts
Telehealth - Such a big DISAPPOINTMENT per analysts
Why digital health has been such a disappointment, and how to change that
Neal Khosla :
Teladoc, a publicly-listed telemedicine company? Well, adoption of virtual doctor visits and utilization among users continues to be low at less than 10 percent. Despite all the hype and fast growth, Teladoc remains an infrequent way to treat urgent care conditions. And this is fine, but hardly transformative. Ask any insurance executive whether telehealth has materially impacted cost or patient access (spoiler alert: they’ll say no and they might even say it has increased costs.)
What other digital health companies could qualify? Livongo? It’s got a $2 billion market cap, down almost 50 percent from its July I.P.O. Health Catalyst? $1.2 billion in market cap and down since IPO. Phreesia? It just crossed the $1 billion market cap threshold. These companies pale in comparison to the massive wins elsewhere in software (Stripe, Uber, Airbnb, Square, and others) and the jury is still out on all of them. They have incrementally improved the efficiency of existing resources, but in my view they have not dramatically improved or scaled healthcare expertise.
Livongo has perhaps been digital health’s biggest success, but it feels like we should see more change in the industry given the investment.
Let’s face it: digital health has been one of the most disappointing investment areas of the last two decades. Venture investors have yet to formulate a strategy that works in health care. The approaches from technology entrepreneurs have been underwhelming. https://www.cnbc.com/2019/12/15/neal-khosla-on-why-digital-health-has-been-so-disappointing.html
mpo